Mode of inactivation of arenaviruses by disulfide-based compounds

Antiviral Research

Volumn 55, Issue 3, 2002, Pages 437-446

  Garcia C C ^a   Candurra, N A ^a   Damonte, E B ^a  

^a Laboratorio de Virologia Ciudad Autonoma de Buenos Aires   (Argentina)

Author keywords

Antiviral; Arenaviruses; Disulfides; Junin virus; Tacaribe virus; Virus inactivation

Indexed keywords

ANTIVIRUS AGENT; DISULFIDE; N 2 100 6; NSC 20625; NSC 4493; NSC 624125; NSC 624151; NSC 624152; NSC 677459; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ARENAVIRUS; ARTICLE; BINDING KINETICS; CONCENTRATION RESPONSE; CONTROLLED STUDY; IC 50; JUNIN VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; TIME; VERO CELL; VIRION; VIRUS INACTIVATION; VIRUS PARTICLE; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; ARENAVIRUSES, NEW WORLD; CERCOPITHECUS AETHIOPS; DISULFIDES; JUNIN VIRUS; VERO CELLS; VIRAL PROTEINS; VIRION; VIRUS REPLICATION;

ARGENTINA (FISH); JUNIN VIRUS; TACARIBE VIRUS;

EID: 0036752588     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(02)00076-1     Document Type: Article

References (39)

1. Andrei G., De Clercq E. Inhibitory effect of selected antiviral compounds on arenavirus replication in vitro. Antiviral Res. 14:1990;287-300.
2. Auperin D.D. Construction and evaluation of recombinant virus vaccines for Lassa fever. Salvato M.S., The Arenaviridae. 1993;259-280 Plenum Press, New York.
3. Bartolotta S., García C.C., Candurra N.A., Damonte E.B. Effect of fatty acids on arenavirus replication: inhibition of virus production by lauric acid. Arch. Virol. 146:2001;777-790.
4. Berthoux L., Péchoux C., Darlix J.L. Multiple effects of an anti-human immunodeficiency virus nucleocapsid inhibitor on virus morphology and replication. J. Virol. 73:1999;10000-10009.
5. Bowen M.D., Peters C.J., Nichol S.T. The phylogeny of New World (Tacaribe Complex) arenaviruses. Virology. 219:1996;285-290.
6. Buchmeier, M.J., Clegg, J.C.S., Franze-Fernandez, M.T., Kolakofsky, D., Peters, C.J., Southern, P.J. 1995. "Arenaviruses". Report of the International Committee on Taxonomy of viruses. Springer-Verlag, N.Y., 319-323.
7. Campbell Dwyer E.J., Lai H., MacDonald R.C., Salvato M.S., Borden K.L.B. The lymphocytic choriomeningitis virus RING protein Z associates with eukaryotic initiation factor 4E and selectively represses translation in a RING-dependent manner. J. Virol. 74:2000;3293-3300.
8. Candurra N.A., Maskin L., Damonte E.B. Inhibition of arenavirus multiplication in vitro by phenotiazines. Antiviral Res. 31:1996;149-158.
9. Castilla V., Mersich S.E., Candurra N.A., Damonte E.B. The entry of Junin virus into Vero cells. Arch. Virol. 136:1994;363-374.
10. Cordo S.M., Candurra N.A., Damonte E.B. Myristic acid analogs are inhibitors of Junin virus replication. Microbes Infect. 1:1999;609-614.
11. Damonte E.B., Mersich S.E., Candurra N.A. Intracellular processing and transport of Junin virus glycoproteins influences virion infectivity. Virus Res. 34:1994;317-326.
12. Di Simone C., Zandonatti M.A., Buchmeier M.J. Acidic pH triggers LCMV membrane fusion activity and conformational change in the glycoprotein spike. Virology. 198:1994;455-465.
13. Enría D.A., Maiztegui J.I. Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res. 23:1994;23-31.
14. Enria D., Feuillade M.R., Levis S., Briggiler A.M., Ambrosio A.M., Saavedra M.C., Becker J.L., Riera L., Calderón G., Pini N., Sottosanti J., Avilés G., García J., Sabattini M. Impact of vaccination of a high-risk population for Argentine hemorrhagic fever with a live-attenuated Junin virus vaccine. Saluzzo J.F., Dodet B., Factors in the Emergence and Control for Rodent-Borne Viral Diseases. 1999;273-279 Elsevier, Paris.
15. Enserink M. Emerging diseases. New arenavirus blamed for recent deaths in California. Science. 289:2000;842-843.
16. Fulhorst C.F., Bowen M.D., Salas R.A., de Manzione N.M.C., Duno G., Utrera A., Ksiazek T.G., Peters C.J., Nichol S.T., de Miller E., Tovar D., Ramos B., Vasquez C., Tesh R.B. Isolation and characterization of Pirital virus, a newly discovered South American arenavirus. Am. J. Trop. Med. Hyg. 56:1997;548-553.
17. Fulhorst C.F., Charrell R.M., Weaver S.C., Ksiazek T.G., Bradley R.D., Milazzo M.L., Tesh R.B., Bowen M.D. Geographic distribution and genetic diversity of Whitewater Arroyo virus in the southwestern United States. Emerg. Infect. Dis. 7:2001;403-407.
18. García C.C., Candurra N.A., Damonte E.B. Antiviral and virucidal activities against arenaviruses of zinc-finger active compounds. Antiviral Chem. Chemother. 11:2000;231-237.
19. Garcin D., Rochat S., Kolakofsky D. The Tacaribe arenavirus small zinc finger protein is required for both mRNA synthesis and genome replication. J. Virol. 67:1993;807-812.
20. Lee K.J., Novella I.S., Teng M.N., Oldstone M.B.A., de la Torre J.C. NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs. J. Virol. 74:2000;3470-3477.
21. López N., Scolaro L., Rossi C., Jácamo R., Candurra N., Pujol C., Damonte E.B., Franze-Fernández M.T. Homologous and heterologous glycoproteins induce protection against Junin virus challenge in guinea pigs. J. Gen. Virol. 81:2000;1273-1281.
22. López N., Jácamo R., Franze-Fernández M.T. Transcription and RNA replication of Tacaribe virus genome and antigenome analogs require N and L proteins: Z protein is an inhibitor of these processes. J. Virol. 75:2001;12241-12251.
23. Maiztegui, J.I., Fernández, N., de Damilano, A.J. 1979. Efficacy of immune plasma in treatment of Argentine hemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 2 (8154), 1216-1217.
24. The AHF Study Group, Maiztegui J.I., McKee K.T., Barrera Oro J.G., Harrison L.H., Gibbs P.H., Feuillade M.R., Enría D.A., Briggiler A.M., Levis S.C., Ambrosio A.M., Halsey N.A., Peters C.J. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. J. Infect. Dis. 177:1998;277-283.
25. Martinez Peralta L.A., Coto C.E., Weissenbacher M.C. The Tacaribe complex: the close relationship between a pathogenic (Junin) and a nonpathogenic (Tacaribe) arenavirus. Salvato M.S., The Arenaviridae. 1993;281-298 Plenum Press, New York.
26. McCormick J.B., King I.J., Webb P.A., Scribner C.L., Craven R.B., Johnson K.M., Elliot L.H., Belmont-Williams R. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 314:1986;20-26.
27. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:1983;55-63.
28. Rein A., Ott D.E., Mirro J., Arthur L.O., Rice W., Henderson L.E. Inactivation of murine leukemia virus by compounds that react with the zinc finger in the viral nucleocapsid protein. J. Virol. 70:1996;4966-4972.
29. Rice W.G., Turpin J.A., Schaeffer C.A., Graham L., Clanton D., Buckheit R.W. Jr., Zaharevitz D., Summers M.F., Wallqvist A., Covell D.G. Evaluation of selected chemotypes in coupled cellular and molecular target-based screens identifies novel HIV-1 zinc finger inhibitors. J. Med. Chem. 39:1996;3606-3616.
30. Rice W.G., Baker D.C., Schaeffer C.A., Graham L., Bu M., Terpening S., Clanton D., Schultz R., Bader J.P., Buckheit R.W. Jr., Field L., Singh P.K., Turpin J.A. Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins. Antimicrob. Agents Chemother. 41:1997;419-426.
31. Rossio J.L., Esser M.T., Suryanarayana K., Schneider D.K., Bess J.W. Jr., Vasquez G.M., Wiltrout T.A., Chertova E., Grimes M.K., Sattentau Q., Arthur L.O., Henderson L.E., Lifson J.D. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J. Virol. 72:1998;7992-8001.
32. Salvato M.S. Molecular biology of the prototype arenavirus, lymphocytic choriomeningitis virus. Salvato M.S., The Arenaviridae. 1993;133-156 Plenum Press, New York.
33. Salvato M.S., Shimomaye E.M. The completed sequence of lymphocytic choriomeningitis virus reveals a unique RNA structure and a gene for a zinc finger protein. Virology. 173:1989;1-10.
34. Salvato M.S., Schweighofer K.J., Burns J., Shimomaye E.M. Biochemical and immunological evidence that the 11-kDa zinc-binding protein of lymphocytic choriomeningitis virus is a structural component of the virus. Virus Res. 22:1992;185-198.
35. Smee D.F., Morris J.L.B., Barnard D.L., Van Aerschot A. Selective inhibition of arthropod-borne and arenaviruses in vitro by 3′-fluoro-3′-deoxyadenosine. Antiviral Res. 18:1992;151-162.
36. Tortorici M.A., Ghiringhelli P.D., Lozano M.E., Albarino C.G., Romanowski V. Zinc-binding properties of Junin virus nucleocapsid protein. J. Gen. Virol. 82:2001;121-128.
37. Tummino P.J., Harvey P.J., McQuade T., Domagala J., Gogliotti R., Sanchez J., Song Y., Hupe D. The human immunodeficiency virus type 1 (HIV-1) nucleocapsid protein zinc ejection activity of disulfide benzamides and benzisothiazolones: correlation with anti-HIV and virucidal activities. Antimicob. Agents Chemother. 41:1997;394-400.
38. Weissenbacher M.C., Laguens R.P., Coto C.E. Argentine hemorrhagic fever. Curr. Top. Microbiol. Immunol. 134:1987;79-116.
39. Witvrouw M., Balzarini J., Pannecouque C., Jhaumeer-Laulloo S., Esté J.A., Schols D., Cherepanov P., Schmit J.C., Debyser Z., Vandamme A.M., Desmyter J., Ramadas S.R., De Clercq E. SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus. Antimicrob. Agents Chemother. 41:1997;262-268.